Higher LDL cholesterol levels (≥130 mg/dL) were linked to longer survival in Sardinian nonagenarians, challenging the ...

China: A recent longitudinal study has highlighted the predictive role of low-density lipoprotein cholesterol (LDL-C) in ...

The following is a summary of “Association between RC/HDL-C and hyperuricemia in adults: evidence from NHANES 2005-2018,” ...

Lerodalcibep is an adnectin-based, small protein-binding, third generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

为明确 LDL-C 是否为 GDM 的危险因素，四川大学华西第二医院的研究人员开展了血清 LDL-C 水平与 GDM 风险相关性的研究。结果发现 LDL-C 水平降低与 GDM 风险增加有关。该研究为 GDM 的防治提供新 ...

This article showcases a curated list of standout studies over the last week on topics such as cholesterol, GLP-1 drugs for ...

A set of identical twins decided to test it out when one of them went vegan and the other didn’t.

Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth.

为解决 PCSK9 抑制剂治疗 ASCVD 患者时 LDL-C 未达标问题，北京安贞医院研究人员开展相关研究，找出 NTR-LDLC 的风险因素并构建预测模型。该研究对优化治疗、改善患者预后意义重大，值得科研读者一读。

A study found that typical cholesterol exams could be missing an important indicator of heart disease risk in certain people.

在中国，2023年的血脂管理指南同样建议超高危人群将LDL-C目标值设为<1.4mmol/L，且基线降低幅度需超过50%。工作组强调，临床医生在制定治疗计划时，需充分考虑患者的个体需求及价值，兼顾治疗风险、经济负担与公平性，以推动更加个性化的药物管理策略。 返回搜狐，查看更多 ...

锐正基因自主开发的ART002是一款以LNP为载体的体内基因编辑新药，旨在通过单次用药，精准编辑LDL-C调控基因PCSK9，以达到持久降低LDL-C水平、降低心血管疾病发病风险的目标。